Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease.
Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice? In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.
Written by:
D'Angelillo RM, Franco P, De Bari B, Fiorentino A, Arcangeli S, Alongi F. Are you the author?
Radiation Oncology Campus Bio-Medico University, Rome Italy; Department of Oncology, Radiation Oncology, University of Turin School of Medicine, Turin, Italy; Radiation Oncology Department, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne Switzerland; Radiation Oncology Department, Sacro Cuore-Don Calabria Hospital, Negrar-Verona, Italy; Radiation Oncology, Azienda Ospedaliera S. Camillo-Forlanini, Rome, Italy.
Reference: Crit Rev Oncol Hematol. 2015 Feb;93(2):136-148.
doi: 10.1016/j.critrevonc.2014.10.003
PubMed Abstract
PMID: 25459667